// scripts/qa/frontier-terra-ryr2-aki.test.mjs
// Verification suite for T-CLIN-126 through T-CLIN-130

import test from 'node:test'
import assert from 'node:assert/strict'

import {
  evaluateTerraRloopDynamics,
} from '../../src/lib/discovery/terraRloopTelomericChromatinEngine.ts'

import {
  evaluateHscQuiescenceDynamics,
} from '../../src/lib/discovery/hscQuiescenceNicheCxcl12Engine.ts'

import {
  evaluateP62Keap1Nrf2Dynamics,
} from '../../src/lib/discovery/p62Keap1Nrf2AutophagyCrossRegulationEngine.ts'

import {
  evaluateCardiomyocyteCalciumDynamics,
} from '../../src/lib/discovery/cardiomyocyteRyr2Serca2aCalciumEngine.ts'

import {
  evaluateAkiKdigoVancomycinTdm,
} from '../../src/domains/clinical-operations/model/acuteKidneyInjuryKdigoVancomycinCds.ts'

// ==========================================
// T-CLIN-126: Telomeric TERRA R-Loop & Chromatin Packaging Engine
// ==========================================
test('T-CLIN-126: TERRA R-loop persistence, replication fork stall & ALT recombination propensity', () => {
  // 1. Homeostatic telomeric chromatin with active RNase H resolution
  const homeostaticTerra = evaluateTerraRloopDynamics({
    subtelomericTerraTranscriptionRateRatio: 1.0,
    rnaseH1H2ResolutionActivityRatio: 1.0,
    shelterinTrf2CappingLevelRatio: 1.0,
  })

  assert.ok(homeostaticTerra.telomericRloopAbundanceIndex < 0.40)
  assert.ok(homeostaticTerra.replicationForkStallProbabilityPerTelomere < 0.30)
  assert.equal(homeostaticTerra.telomereFragilityClassification, 'STABLE_CAPPED_PACKAGING')
  assert.ok(homeostaticTerra.subtelomericH3K9me3DensityFeedbackScore > 0.3)
  assert.equal(homeostaticTerra.metadata.truthClass, 'mechanistic_simulation_proxy')

  // 2. High TERRA transcription in ALT cancer cells with low RNase H driving recombination
  const altCancerCells = evaluateTerraRloopDynamics({
    subtelomericTerraTranscriptionRateRatio: 3.5,
    rnaseH1H2ResolutionActivityRatio: 0.20,
    altPathwayActive: true,
  })

  assert.ok(altCancerCells.telomericRloopAbundanceIndex > 0.70)
  assert.ok(altCancerCells.replicationForkStallProbabilityPerTelomere > 0.50)
  assert.ok(altCancerCells.homologyDirectedAltRecombinationPropensity > 0.60)
  assert.equal(altCancerCells.telomereFragilityClassification, 'COLLAPSED_REPLICATION_FORK_CRISIS')
})

// ==========================================
// T-CLIN-127: Hematopoietic Stem Cell Quiescence & CXCL12 Niche Engine
// ==========================================
test('T-CLIN-127: Bone marrow niche retention, p57Kip2 dormancy & Plerixafor (AMD3100) mobilization', () => {
  // 1. Pristine endosteal niche dormancy in LT-HSCs
  const dormantNiche = evaluateHscQuiescenceDynamics({
    boneMarrowCxcl12ConcentrationNgMl: 28,
    hscCxcr4ReceptorDensityRatio: 1.0,
    thrombopoietinTpoSignalingRatio: 1.0,
    boneMarrowHypoxicNichePo2MmHg: 15,
  })

  assert.ok(dormantNiche.nicheRetentionAnchoringScore >= 0.85)
  assert.ok(dormantNiche.g0QuiescentFractionPercentage >= 80.0)
  assert.ok(dormantNiche.p57Kip2CyclinInhibitorExpressionIndex > 0.60)
  assert.equal(dormantNiche.hscLongTermSelfRenewalCapacityStatus, 'PRESERVED_LONG_TERM_DORMANCY')
  assert.equal(dormantNiche.metadata.truthClass, 'mechanistic_simulation_proxy')

  // 2. Pharmacological mobilization with CXCR4 antagonist Plerixafor
  const mobilizedStemCells = evaluateHscQuiescenceDynamics({
    boneMarrowCxcl12ConcentrationNgMl: 28,
    hscCxcr4ReceptorDensityRatio: 1.0,
    thrombopoietinTpoSignalingRatio: 1.0,
    boneMarrowHypoxicNichePo2MmHg: 15,
    plerixaforAmd3100ConcentrationUm: 2.5,
  })

  assert.ok(mobilizedStemCells.nicheRetentionAnchoringScore < 0.35)
  assert.ok(mobilizedStemCells.peripheralBloodCd34MobilizationYieldPerHour > 40.0)
  assert.ok(mobilizedStemCells.plerixaforMobilizationFoldIncrease > 8.0)
})

// ==========================================
// T-CLIN-128: Autophagy Receptor p62/SQSTM1-KEAP1-NRF2 Cross-Regulation Engine
// ==========================================
test('T-CLIN-128: p62 Ser351 phosphorylation, non-canonical KEAP1 sequestration & NRF2 ARE induction', () => {
  // 1. Basal unstressed cell
  const basalRedox = evaluateP62Keap1Nrf2Dynamics({
    p62Sqstm1TotalAbundanceRatio: 1.0,
    p62Ser351PhosphorylationRatio: 0.05,
    autophagicFluxClearanceCapacityRatio: 1.0,
  })

  assert.ok(basalRedox.p62Keap1CompetitiveBindingIntensity < 0.20)
  assert.ok(basalRedox.nrf2NuclearTranslocationFold < 2.5)
  assert.equal(basalRedox.cellularRedoxAdaptationClassification, 'BASAL_UNSTRESSED_HOMEOSTASIS')
  assert.equal(basalRedox.metadata.truthClass, 'mechanistic_simulation_proxy')

  // 2. High p62 phosphorylation (Ser351) under oxidative stress sequestering KEAP1
  const inducedNrf2 = evaluateP62Keap1Nrf2Dynamics({
    p62Sqstm1TotalAbundanceRatio: 2.2,
    p62Ser351PhosphorylationRatio: 0.85,
    autophagicFluxClearanceCapacityRatio: 1.0,
    electrophilicOxidativeStressConcentrationUm: 15.0,
  })

  assert.ok(inducedNrf2.p62Keap1CompetitiveBindingIntensity > 0.65)
  assert.ok(inducedNrf2.nrf2NuclearTranslocationFold >= 4.0)
  assert.ok(inducedNrf2.targetGeneInductionProfiles.hmox1HemeOxygenase1InductionFold > 4.0)
  assert.ok(inducedNrf2.glutathioneRedoxBufferingCapacityPercentage > 60.0)
  assert.equal(inducedNrf2.cellularRedoxAdaptationClassification, 'ADAPTIVE_ANTIOXIDANT_SHIELDING')
})

// ==========================================
// T-CLIN-129: Cardiomyocyte Calcium Handling, RyR2 Leak & SERCA2a Phospholamban Engine
// ==========================================
test('T-CLIN-129: Sarcoplasmic RyR2 leak, DAD arrhythmia trigger & beta-blocker lusitropic stabilization', () => {
  // 1. Healthy ventricular cardiomyocyte excitation-contraction coupling
  const healthyCalcium = evaluateCardiomyocyteCalciumDynamics({
    ryr2ReceptorClusterDensityRatio: 1.0,
    serca2aPumpActivityRatio: 1.0,
    phospholambanSer16PhosphorylationRatio: 0.40,
  })

  assert.ok(healthyCalcium.peakSystolicCalciumMicromolar >= 0.90)
  assert.ok(healthyCalcium.diastolicRestingCalciumNanomolar <= 130.0)
  assert.ok(healthyCalcium.calciumTransientDecayTauMilliseconds < 300.0)
  assert.equal(healthyCalcium.delayedAfterdepolarizationArrhythmiaRiskTier, 'LOW_HOMOGENEOUS_COUPLING')
  assert.equal(healthyCalcium.metadata.truthClass, 'mechanistic_simulation_proxy')

  // 2. Pathological RyR2 diastolic leak triggering CPVT / VT risk
  const leakyCardiomyocyte = evaluateCardiomyocyteCalciumDynamics({
    ryr2ReceptorClusterDensityRatio: 1.4,
    ryr2DiastolicLeakPresent: true,
    serca2aPumpActivityRatio: 0.70,
    phospholambanSer16PhosphorylationRatio: 0.20,
  })

  assert.ok(leakyCardiomyocyte.diastolicRestingCalciumNanomolar > 140.0)
  assert.equal(leakyCardiomyocyte.delayedAfterdepolarizationArrhythmiaRiskTier, 'CRITICAL_CPVT_VENTRICULAR_TACHYCARDIA_TRIGGER')

  // 3. Beta-blocker protection mitigating afterdepolarization risk
  const betaBlockerTreated = evaluateCardiomyocyteCalciumDynamics({
    ryr2ReceptorClusterDensityRatio: 1.4,
    ryr2DiastolicLeakPresent: true,
    serca2aPumpActivityRatio: 0.70,
    phospholambanSer16PhosphorylationRatio: 0.20,
    betaBlockerTherapyPresent: true,
  })

  assert.ok(betaBlockerTreated.diastolicRestingCalciumNanomolar < leakyCardiomyocyte.diastolicRestingCalciumNanomolar)
  assert.equal(betaBlockerTreated.delayedAfterdepolarizationArrhythmiaRiskTier, 'MODERATE_AFTERDEPOLARIZATION_VULNERABILITY')
})

// ==========================================
// T-CLIN-130: Clinical Acute Kidney Injury KDIGO Staging & Vancomycin TDM CDS Engine
// ==========================================
test('T-CLIN-130: KDIGO AKI staging, Vancomycin AUC24 target & Pip-Tazo nephrotoxic synergy alerts', () => {
  // 1. Patient with optimal Vancomycin AUC and preserved renal function
  const optimalPatient = evaluateAkiKdigoVancomycinTdm({
    patientId: 'PT-AKI-001',
    baselineSerumCreatinineMgDl: 0.9,
    currentSerumCreatinineMgDl: 0.95,
    currentVancomycinDoseMg: 1000,
    currentVancomycinFrequencyHours: 12,
    measuredVancomycinTroughMcgMl: 15.0, // 15.0 * 32.5 = ~488 mg*h/L AUC
    concomitantNephrotoxins: [],
  })

  assert.equal(optimalPatient.kdigoAkiStage, 'NO_AKI')
  assert.ok(optimalPatient.estimatedVancomycinAuc24MgHrL >= 400 && optimalPatient.estimatedVancomycinAuc24MgHrL <= 600)
  assert.equal(optimalPatient.vancomycinTherapeuticWindowStatus, 'OPTIMAL_TARGET_AUC_400_TO_600')
  assert.equal(optimalPatient.vancomycinDosageAdjustmentRecommendation.recommendedAction, 'MAINTAIN_CURRENT_REGIMEN')
  assert.equal(optimalPatient.nephrotoxicSynergyAlert, false)
  assert.equal(optimalPatient.truthClass, 'clinical_decision_support_guideline_proxy')
  assert.equal(optimalPatient.auditDigestSha256.length, 64)

  // 2. High-risk KDIGO Stage 3 AKI with Vancomycin + Piperacillin-Tazobactam synergy
  const criticalAkiPatient = evaluateAkiKdigoVancomycinTdm({
    patientId: 'PT-AKI-002',
    baselineSerumCreatinineMgDl: 1.0,
    currentSerumCreatinineMgDl: 3.2, // 3.2x baseline -> Stage 3
    historicalCreatinine48HoursAgoMgDl: 1.8,
    urineOutputMlKgHourLast6Hours: 0.2, // anuria / oliguria (<0.3)
    currentVancomycinDoseMg: 1250,
    currentVancomycinFrequencyHours: 12,
    measuredVancomycinTroughMcgMl: 26.5, // supratherapeutic
    concomitantNephrotoxins: ['PIPERACILLIN_TAZOBACTAM'],
  })

  assert.equal(criticalAkiPatient.kdigoAkiStage, 'STAGE_3_SEVERE_FAILURE_OR_ANURIA')
  assert.ok(criticalAkiPatient.estimatedVancomycinAuc24MgHrL > 600)
  assert.equal(criticalAkiPatient.vancomycinTherapeuticWindowStatus, 'SUPRATHERAPEUTIC_NEPHROTOXIC_AUC_GREATER_THAN_600')
  assert.equal(criticalAkiPatient.vancomycinDosageAdjustmentRecommendation.recommendedAction, 'HOLD_AND_REDUCE_DOSE_OR_INTERVAL')
  assert.equal(criticalAkiPatient.nephrotoxicSynergyAlert, true)
  assert.equal(criticalAkiPatient.renalReplacementTherapyEscalationAlert, true)
  assert.ok(criticalAkiPatient.safetyBoundaryAlerts.some((a) => a.includes('CRITICAL NEPHROTOXIC SYNERGY')))
})
